Patents by Inventor Johan Hansson

Johan Hansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11943009
    Abstract: A communication barrier arrangement includes a first driver having a first interface for receiving signals from a first device destined for a second device, an isolation barrier including a first transformer for signal transfer and having a primary winding connected to the first driver and a secondary winding, a second driver connected to the secondary winding and having a first connection terminal for output of the signals towards the second device, a first signal conditioner having a second connection terminal for receiving the signals from the second driver and a second interface for delivering them to the second device and a protection circuit including a resistor in parallel with a first capacitor, the protection circuit being connected between the first and second connection terminals.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: March 26, 2024
    Inventors: Ulf Hansson, Thomas Keul, Johan Wennerberg
  • Patent number: 8915385
    Abstract: A coupler head for a coupling arrangement is shown, which coupler head includes a coupler head housing (6) extending in a longitudinal direction from a first end (6a), attachable to a drawbar, to a second end (6b), which is arranged to carry a coupling interface between coupled rail vehicles, which coupler head housing houses mechanical coupling components (8,9) effective for automatic coupling to the corresponding components of a connecting coupling arrangement. The coupler head is characterized in that the coupler head housing has at least one notch (11, 11?) for a predetermined and primarily axial compression thereof with absorption of energy from a deforming compressive force that is applied to the coupler head in the longitudinal direction thereof. The coupler head has preferably at least one notch (11, 11?) for a predetermined folding of the coupler head housing.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: December 23, 2014
    Assignee: Ego International B.V.
    Inventors: Johan Hansson, Mattias Hjort, Fredrik Hiswåls, Daniel Larsson, Anders Svedbo, Anders Westman
  • Publication number: 20130105431
    Abstract: A coupler head for a coupling arrangement is shown, which coupler head includes a coupler head housing (6) extending in a longitudinal direction from a first end (6a), attachable to a drawbar, to a second end (6b), which is arranged to carry a coupling interface between coupled rail vehicles, which coupler head housing houses mechanical coupling components (8,9) effective for automatic coupling to the corresponding components of a connecting coupling arrangement. The coupler head is characterized in that the coupler head housing has at least one notch (11, 11?) for a predetermined and primarily axial compression thereof with absorption of energy from a deforming compressive force that is applied to the coupler head in the longitudinal direction thereof. The coupler head has preferably at least one notch (11, 11?) for a predetermined folding of the coupler head housing.
    Type: Application
    Filed: June 8, 2011
    Publication date: May 2, 2013
    Applicant: EGO INTERNATIONAL B.V.
    Inventors: Johan Hansson, Mattias Hjort, Fredrik Hiswåls, Daniel Larsson, Anders Svedbo, Anders Westman
  • Publication number: 20110136843
    Abstract: The present invention relates to a combination of (a) a chemokine receptor 1 (CCR1) antagonist and (b) a muscarinic antagonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treatment of airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases.
    Type: Application
    Filed: February 21, 2008
    Publication date: June 9, 2011
    Inventors: Tomas Eriksson, Johan Hansson, Marguerite Mensonides-Harsema, John Mo
  • Publication number: 20110124613
    Abstract: The present invention provides a pharmaceutical product comprising, in combination of, (a) a (therapeutically effective) dose of a first active ingredient, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient, which is a glucocorticoid receptor agonist; and optionally, (c) a (therapeutically effective) dose of a third active ingredient, which is a ?2-agonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating treatment of airway diseases, especially chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases such as COPD and asthma.
    Type: Application
    Filed: February 21, 2008
    Publication date: May 26, 2011
    Inventors: Tomas Eriksson, Johan Hansson, Marguerite Mensonides-Harsema, John Mo
  • Patent number: 7788983
    Abstract: A sensor arrangement is arranged to detect at least one position of a displaceable component in a fluid device, which fluid device comprises a wall enclosing a cavity, in which cavity the component is displaced by pressurized fluid selectively applied to the component. The sensor arrangement includes a magnetic sensor mounted outside the wall and a first sensor element that is connected to the magnetic sensor and extends through the wall and a predetermined distance into the cavity. The magnetic sensor is arranged to detect the position of at least one predetermined second sensor element located on the displaceable component by sensing a change in magnetic flux induced in the first sensor element by the second sensor element.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: September 7, 2010
    Assignee: Parker-Hannifin Corporation
    Inventors: Johan Hansson, Ulf Nyberg
  • Publication number: 20090298875
    Abstract: The present invention provides pharmaceutical compositions comprising a ?2-agonist, and a compound of formula: wherein m, R1, R2, R3, and R4 are as defined in the specification, and their use in therapy.
    Type: Application
    Filed: August 24, 2006
    Publication date: December 3, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Tomas Eriksson, Johan Hansson
  • Publication number: 20090261819
    Abstract: A sensor arrangement is arranged to detect at least one position of a displaceable component in a fluid device, which fluid device comprises a wall enclosing a cavity, in which cavity the component is displaced by pressurized fluid selectively applied to the component. The sensor arrangement includes a magnetic sensor mounted outside the wall and a first sensor element that is connected to the magnetic sensor and extends through the wall and a predetermined distance into the cavity. The magnetic sensor is arranged to detect the position of at least one predetermined second sensor element located on the displaceable component by sensing a change in magnetic flux induced in the first sensor element by the second sensor element.
    Type: Application
    Filed: April 9, 2009
    Publication date: October 22, 2009
    Applicant: PARKER HANNIFIN AB
    Inventors: Johan Hansson, Ulf Nyberg
  • Publication number: 20090215732
    Abstract: The present invention provides pharmaceutical compositions comprising a glucocorticosteroid and a compound of formula: wherein m, R1, R2, R3, and R4 are as defined in the specification, and their use in therapy.
    Type: Application
    Filed: August 24, 2006
    Publication date: August 27, 2009
    Inventors: Tomas Eriksson, Johan Hansson
  • Patent number: 7226595
    Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV?, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs. An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: June 5, 2007
    Assignee: Active Biotech A.B.
    Inventors: Per Antonsson, Per Bjork, Mikael Dohlsten, Terje Kalland, Lars Abrahmsen, Johan Hansson, Göran Forsberg
  • Publication number: 20060104204
    Abstract: A message that comprises encoded bits interleaved over N transmission bursts, wherein N is greater than 1, is received by receiving fewer than N of the transmission bursts, whereby there exist remaining ones of the N transmission bursts that have not been received. All of the received transmission bursts are decoded to generate decoded data. It is then determined whether the decoded data is error free. Reception of remaining transmission bursts of the message is inhibited if the decoded data is error free, otherwise one or more remaining ones of the N transmission bursts are received.
    Type: Application
    Filed: November 12, 2004
    Publication date: May 18, 2006
    Inventors: Johan Hansson, Goran Pehrsson, Emma Wittenmark, Bjorn Rikte
  • Patent number: 6750656
    Abstract: A technique for estimating current consumption of an electronic device such that current consumed during reception of bursts is utilized in calculating the remaining battery power. By determining the time duration of each reception burst and the charge consumed during each burst, the total charge consumed by the reception bursts is calculated. The total charge calculated is used to determine the remaining battery power.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: June 15, 2004
    Assignee: Telefonaktiebolaget LM Ericsson(PUBL)
    Inventors: Kent-Inge Ingesson, Johan Hansson, Kristoffer Ptasinski
  • Publication number: 20040046565
    Abstract: A technique for estimating current consumption of an electronic device such that current consumed during reception of bursts is utilized in calculating the remaining battery power. By determining the time duration of each reception burst and the charge consumed during each burst, the total charge consumed by the reception bursts is calculated. The total charge calculated is used to determine the remaining battery power.
    Type: Application
    Filed: September 10, 2002
    Publication date: March 11, 2004
    Inventors: Kent-Inge Ingesson, Johan Hansson, Kristoffer Ptasinski
  • Publication number: 20030092894
    Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV&bgr;, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells.
    Type: Application
    Filed: October 30, 2002
    Publication date: May 15, 2003
    Applicant: Pharmacia AB, Uppsala Sweden
    Inventors: Per Antonsson, Per Bjork, Mikael Dohlsten, Terje Kalland, Johan Hansson, Goran Forsberg, Lars Abrahmsen
  • Patent number: 6514498
    Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, referably TCRV&bgr;, and T cell activation has been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In a preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs.
    Type: Grant
    Filed: August 12, 1996
    Date of Patent: February 4, 2003
    Assignee: Pharmacia AB
    Inventors: Per Antonsson, Per Björk, Mikael Dohlsten, Johan Hansson, Göran Forsberg, Lars Abrahmsén, Terje Kalland
  • Patent number: 5836950
    Abstract: The present invention relates to a guide instrument which is adapted for use at operations for fixation of bone fragments at bone fractures, preferably femoral neck fractures, whereby the bone fragments are intended to be fixed relative to each other by means of at least two bone screws, whereby the guide instrument (1) is adapted for guiding a first and a second drill steel which are adapted for drilling passages in the bone fragments for the bone screws. The guide instrument (1) is designed to permit guiding of the drill steels, driving through of threaded front portions of the bone screws and guiding of uptapped or unthreaded rear portions of said bone screws.
    Type: Grant
    Filed: May 13, 1997
    Date of Patent: November 17, 1998
    Inventor: Henrik Lars Johan Hansson